J. Goldman & CO LP Arrowhead Pharmaceuticals, Inc. Transaction History
J. Goldman & CO LP
- $3.53 Billion
- Q4 2024
A detailed history of J. Goldman & CO LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 13,500 shares of ARWR stock, worth $268,650. This represents 0.05% of its overall portfolio holdings.
Number of Shares
13,500Holding current value
$268,650% of portfolio
0.05%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ARWR
# of Institutions
305Shares Held
95.9MCall Options Held
523KPut Options Held
493K-
Black Rock Inc. New York, NY15.7MShares$312 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$242 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$221 Million3.04% of portfolio
-
State Street Corp Boston, MA6.02MShares$120 Million0.0% of portfolio
-
Slate Path Capital LP New York, NY5.23MShares$104 Million1.89% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.11B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...